PD-L2 Nuclear Localization Analysis for Therapy Response Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately predict patient response to therapies due to the lack of understanding of PD-L2 localization in cells, leading to ineffective treatment strategies and immune dysfunction.
Innovation Solution
Analyzing the cellular distribution of PD-L2, particularly its nuclear localization, to determine the likelihood of patient response to therapies such as anti-infective, cytotoxic, or immunotherapy, using methods that detect PD-L2 levels and co-localization with histone polypeptides to predict resistance or sensitivity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to predict patient response to therapy, then treatment strategies can be implemented, but prediction accuracy is insufficient leading to ineffective treatments
Solution Approach 1:
The invention changes the parameter being measured from general PD-L2 expression levels to specific nuclear localization of PD-L2. This parameter change enables more accurate prediction of patient response to therapy by detecting the presence or absence of nuclear PD-L2, which correlates with resistance to immunotherapy, thereby improving both measurement precision and treatment reliability
Solution Approach 2:
The invention introduces nuclear localization of PD-L2 as an intermediary marker that mediates between the complex immune system state and the binary outcome of treatment response. This intermediary provides a measurable indicator that accurately reflects the underlying biological state, enabling reliable prediction of therapy effectiveness
2Measurement precision
If PD-L2 expression is analyzed without considering localization, then analysis is simpler, but prediction of therapy response is inaccurate
Solution Approach 1:
The invention applies local quality by distinguishing PD-L2 based on its cellular location. Rather than treating all PD-L2 expression equally, the method specifically identifies and measures nuclear PD-L2, recognizing that the local position of the protein within the cell determines its functional significance for predicting immunotherapy response
Solution Approach 2:
The invention segments the analysis into distinct cellular compartments, specifically isolating nuclear PD-L2 from cytoplasmic or membrane PD-L2. This segmentation allows for precise measurement of the nuclear fraction, which is the critical predictor of therapy resistance, while maintaining a manageable analytical approach through targeted detection methods
3Measurement precision
If nuclear localization of PD-L2 is detected, then therapy response can be accurately predicted, but detection methods become more complex
Solution Approach 1:
The invention uses co-localization with histone proteins as an intermediary approach to detect nuclear PD-L2. Rather than directly imaging nuclear PD-L2 which would require complex techniques, the method detects the association between PD-L2 and histone proteins, which naturally occur in the nucleus. This intermediary detection strategy achieves high measurement precision while managing detection complexity
Solution Approach 2:
The invention creates a measurable copy or proxy signal for nuclear PD-L2 by detecting its co-localization with histone proteins. This proxy measurement allows indirect but accurate detection of nuclear PD-L2 presence, achieving high measurement precision through a more manageable detection approach that leverages the known nuclear localization of histones
Data Source
AI summary
Disclosed are methods and agents for predicting response to therapy, immune status and/or disease progression. More particularly, disclosed are methods, agents and kits for analyzing cellular distribution of PD-L2, including its nuclear localization, for stratifying a patient as a likely responder or non-responder to a therapy, for predicting treatment outcome of a patient with a therapy, for managing treatment of a patient with a therapy, for monitoring a disease in a patient following treatment with a therapy, for determining the status of a disease and/or for determining the immune status of a patient.